BOHEMIA
Broad One Health Endectocide-based Malaria Intervention in Africa
- Duración
- Feb 2019 - Feb 2023
- Coordinador
- Regina Rabinovich
- Financiadores
- UNITAID
- Página web
- http://bohemiaconsortium.org
The world is not on track to achieve the goals proposed by WHO in the Global Technical Strategy for Malaria 2016-2030 (GTS), and currently available tools are unlikely to suffice. Vector control, our most effective strategy, is now doubly threatened by widespread insecticide resistance and residual transmission caused by mosquito behavioral adaptations that allow them to elude home-based vector control tools such as treated bed nets and indoor residual spraying.
Ivermectin is an antiparasitic drug distributed to more than 2.5 billion people over the last 30 years in mass drug administration campaigns to directly treat two Neglected Tropical Diseases (NTDs). More recently, it has been noted that ivermectin can also increase the mortality of mosquitoes that feed on treated humans or animals during a time period that can be up to 28 days, depending on the dose.
Thus, Mass Drug Administration (MDA) of ivermectin to humans and/or livestock holds potential to complement the malaria toolbox by tackling residual transmission and help the malaria community get back on track to achieve the GTS goals.
Objectives
BOHEMIA will evaluate the MDA of ivermectin to humans and/or livestock in two African countries -Tanzania and Mozambique- during the malaria season, and will collect data on the epidemiological impact to support normative guidance, global and national policy change.
Should evidence be supportive, engagement with WHO and other key stakeholders will support the conditions for a policy recommendation, and subsequent national adoption.
BOHEMIA combines evidence generation and stakeholder engagement to enable the path for policy and implementation of ivermectin as a new vector control tool complementary to standard tools (treated bed nets and indoor residual spraying).
The Consortium
The BOHEMIAconsortium is led by ISGlobal and includes:
- Centro de Investigaçao em Saúde de Manhiça
- Ifakara Health Institute
- University Hospital Bern
- University of Oxford
- Virginia Tech
Total funding
25.3 U$ million (awarded by Unitaid)
Nuestro equipo
Principal Investigator
- Nelly Regina Rabinovich Directora de la Iniciativa de Eliminación de la Malaria
ISGlobal team
- Carlos Javier Chaccour
- Mary-Ann Richardson BOHEMIA Clinical Trial Manager
- Paula Ruiz-Castillo Postdoctoral Fellow
- Júlia Montaña Field Epidemiologist
- Patricia Nicolás Predoctoral Fellow
- Paulo Cunha Project Finance Manager
Otros proyectos
Ver proyectos pasadosMESA
The Malaria Eradication Scientific Alliance - MESA is dedicated to advancing the science of malaria eradication.
Estudio inmunológico de la vacuna RTS,S
Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control
Alianza Mozambiqueña para la Eliminación de la Malaria (MALTEM)
Alianza Mozambiqueña para la Eliminación de la Malaria
MiPMon
Pregnant women as a sentinel group for malaria surveillance in an era of changing malaria transmission
Severe malaria and microRNAs
A path towards new diagnostic and prevention tools for severe infectious pathologies
AlphaGal
Exploration of the singularities of the sugar nucleotide metabolism and description of novel glycosylation pathways in the malaria parasite
Epigenetic variation in malaria parasites II
Investigating new aspects of the mechanisms and biological functions of epigenetic variation in malaria parasites
Mechanistic aspects of P. vivax
Mechanistic aspects of anemia and splenomegaly caused by plasmodium vivax, a neglected human parasite
TIPTOP
Transforming IPT for optimal pregnancy
NANOpheles
Development of nanovectors for the targeted delivery in Anopheles mosquitoes of agents blocking transmission of Plasmodium parasites
ASINTMAL
Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults